Study to Assess the Safety and Efficacy of Tacrolimus (Prograf Capsule/Injection) and Methotrexate (MTX) Combination Therapy for Prevention of Graft Versus Host Disease (GVHD) in Patients Who Received Peripheral Hematopoietic Stem Cell Transplantation From a Sibling Donor

A Historically-controlled, Multi-center Study to Assess the Safety and Efficacy of Tacrolimus (Prograf Capsule, Prograf Injection) and Methotrexate Combination Therapy for Prevention of GVHD in Patients Who Received Peripheral Hematopoietic Stem Cell Transplantation From a Sibling Donor

The objective of this study is to assess the safety and efficacy of Tacrolimus (Prograf capsule, Prograf injection) and Methotrexate combination therapy for GVHD prophylaxis in patients who received peripheral hematopoietic stem cell transplantation from a sibling donor, and to compare with data from a historical control group that administered a conventional Cyclosporine formulation.

Inclusion Criteria:

• Blood diseases for a standard risk group

  • Primary remission of AML (acute myeloid leukemia)
  • Primary remission of ALL (acute lymphocytic leukemia)
  • Secondary remission of ALL (acute lymphocytic leukemia)
  • SAA (severe aplastic anemia)
  • Chronic stage CML (chronic myeloid leukemia)
  • MDS (myelodysplastic syndrome)
  • Myeloma (multiple myeloma)

• A patient who received peripheral hematopoietic stem cell transplantation from a HLA-matched sibling donor

Exclusion Criteria:

• A patient with renal impairment (serum creatinine level ≥ 1.5mg/dl or 130μmol/l, GFR≤ 30%)
• A pregnant or breastfeeding woman
• A woman who is unwilling or unable to practice appropriate contraception during the study
• A patient who is highly likely to experience aggravation during treatment due to active tuberculosis, other hepatic disease, hypertension, heart failure, chronic obstructive respiratory disease, etc.
• A patient with hypersensitivity to tacrolimus